We are live on ! Find out more
AZN icon

AstraZeneca

375 hedge funds and large institutions have $6.27B invested in AstraZeneca in 2015 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 139 increasing their positions, 110 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more call options, than puts

Call options by funds: $107M | Put options by funds: $79.6M

26% more repeat investments, than reductions

Existing positions increased: 139 | Existing positions reduced: 110

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

2% more capital invested

Capital invested by funds: $6.17B → $6.27B (+$100M)

0.69% more ownership

Funds ownership: 7.12%7.8% (+0.69%)

8% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 37

3% less funds holding

Funds holding: 385375 (-10)

Holders
375
Holders Change
-10
Holders Change %
-2.6%
% of All Funds
10.11%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.13%
New
34
Increased
139
Reduced
110
Closed
37
Calls
$107M
Puts
$79.6M
Net Calls
+$27.9M
Net Calls Change
-$51.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$41.7M -$2.94M -42,913 -6%
WCM
27
Wedge Capital Management
North Carolina
$40.9M -$8.23M -120,200 -16%
Ameriprise
28
Ameriprise
Minnesota
$36.2M +$25.5M +372,148 +190%
Goldman Sachs
29
Goldman Sachs
New York
$31.9M +$7.9M +115,384 +30%
Arrowstreet Capital
30
Arrowstreet Capital
Massachusetts
$30.9M +$24.6M +358,686 +285%
AG
31
Aperio Group
California
$30M +$1.64M +23,910 +5%
RJA
32
Raymond James & Associates
Florida
$27.5M +$2.97M +43,413 +11%
Millennium Management
33
Millennium Management
New York
$24M +$1.4M +20,512 +6%
BG
34
BlackRock Group
United Kingdom
$22.4M -$2.2M -32,103 -8%
CC
35
Chubb Corp
New Jersey
$22.3M
Citadel Advisors
36
Citadel Advisors
Florida
$21.3M +$8.73M +127,450 +62%
GC
37
Guggenheim Capital
Illinois
$20.9M -$5.95M -86,957 -21%
ClearBridge Investments
38
ClearBridge Investments
New York
$20.1M -$10.2M -148,425 -32%
GT
39
Glenmede Trust
Pennsylvania
$19.3M -$450K -6,574 -2%
Envestnet Asset Management
40
Envestnet Asset Management
Illinois
$19M +$6.31M +92,165 +45%
PPA
41
Parametric Portfolio Associates
Washington
$18.5M +$2.21M +32,215 +12%
USAA
42
United Services Automobile Association
Texas
$17.6M +$3.94M +57,563 +26%
VanEck Associates
43
VanEck Associates
New York
$16.7M +$2.37M +34,592 +15%
TD Asset Management
44
TD Asset Management
Ontario, Canada
$15.7M +$5.54M +80,866 +49%
Capital World Investors
45
Capital World Investors
California
$14.7M
MNA
46
Manning & Napier Advisors
New York
$14.5M
AWCI
47
Alpine Woods Capital Investors
New York
$13.3M
NFA
48
Nationwide Fund Advisors
Ohio
$13M +$362K +5,280 +3%
Two Sigma Investments
49
Two Sigma Investments
New York
$12.8M +$2.04M +29,815 +17%
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$11.9M +$5.55M +81,066 +77%

AZN Hedge Fund Activity: Q2 2015 in Review

375 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2015, worth a combined $6.27B — up 1.6% from $6.17B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of AZN and 34 opened new positions — a net loss of 3 holders — while 110 trimmed existing stakes and 139 added.

The largest buyer was Capital International Investors, adding an estimated $166M. The largest seller was Jane Street, exiting entirely with an estimated $35.7M sold.

  • 375 institutional investors held AstraZeneca (AZN) as of Q2 2015, down from 385 in Q1 2015.
  • Funds reported $6.27B of AstraZeneca stock for Q2 2015, up 1.6% quarter-over-quarter.
  • 34 funds opened new AstraZeneca positions in Q2 2015 and 37 closed out, a net change of -3 holders.
  • The largest AstraZeneca buyer in Q2 2015 was Capital International Investors, an estimated $166M added.
  • The largest AstraZeneca seller in Q2 2015 was Jane Street, an estimated $35.7M sold.

Based on aggregated 13F filings for Q2 2015.